|
|
Blood, 15 September 2007, Vol. 110, No. 6, pp. 2067-2074.
Prepublished online as a Blood First Edition Paper on June 1, 2007; DOI 10.1182/blood-2007-01-069575.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
Samir Parekh1,
Jose M. Polo1,
Rita Shaknovich2,
Przemyslaw Juszczynski3,
Paola Lev1,
Stella M. Ranuncolo1,
Yingnan Yin1,
Ulf Klein4,
Giorgio Cattoretti5,
Riccardo Dalla Favera4,
Margaret A. Shipp3, and
Ari Melnick1
1 Department of Developmental and Molecular Biology;
2 Department of Pathology, Albert Einstein College of Medicine, Bronx, NY;
3 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA;
4 Institute for Cancer Genetics, Columbia University, New York, NY;
5 Department of Pathology, Università degli Studi di Milano-Bicocca, Monza, Italy
The BCL6 transcriptional repressor is the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs). Constitutive expression of BCL6 mediates lymphomagenesis through aberrant proliferation, survival, and differentiation blockade. Binding of BCL6 to the SMRT/N-CoR corepressors mediates the BCL6 survival effect in DLBCL. Although the basis for differentiation blockade is unknown in DLBCL, recent data suggest that BCL6 binding to the MTA3 corepressor might be involved. We report that BCL6 and MTA3 are coexpressed in normal germinal center B cells and DLBCL. Depletion of MTA3 in DLBCL cells induced a differentiation-related BCL6 target gene (PRDM1), but not target genes involved in survival. Accordingly, MTA3 and PRDM1 expression are mutually exclusive in germinal center B cells. We performed chromatin immunoprecipitation (ChIP)–on-chip mapping of the PRDM1 locus, identifying a novel BCL6 binding site on intron 3 of the PRDM1 gene, and show that BCL6 recruits MTA3 to this site. In DLBCL cells, MTA3 depletion induced plasmacytic differentiation but did not decrease viability of DLBCL cells. However, MTA3 depletion synergized with a specific BCL6 inhibitor that blocks SMRT/N-CoR binding to decrease DLBCL viability. Taken together, these results show that BCL6 regulates distinct transcriptional programs through the SMRT/N-CoR and MTA3 corepressors, respectively, and provides a basis for combinatorial therapeutic targeting of BCL6.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Division of labor for oncogene BCL6
- Alexander Dent
Blood 2007 110: 1707-1708.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K. Nie, M. Gomez, P. Landgraf, J.-F. Garcia, Y. Liu, L. H.C. Tan, A. Chadburn, T. Tuschl, D. M. Knowles, and W. Tam
MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas
Am. J. Pathol.,
July 1, 2008;
173(1):
242 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Cerchietti, J. M. Polo, G. F. Da Silva, P. Farinha, R. Shaknovich, R. D. Gascoyne, S. F. Dowdy, and A. Melnick
Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas
Cancer Res.,
May 1, 2008;
68(9):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Mendez, J. M. Polo, J. J. Yu, M. Krupski, B. B. Ding, A. Melnick, and B. H. Ye
CtBP Is an Essential Corepressor for BCL6 Autoregulation
Mol. Cell. Biol.,
April 1, 2008;
28(7):
2175 - 2186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Diehl, H. Schmidlin, M. Nagasawa, S. D. van Haren, M. J. Kwakkenbos, E. Yasuda, T. Beaumont, F. A. Scheeren, and H. Spits
STAT3-Mediated Up-Regulation of BLIMP1 Is Coordinated with BCL6 Down-Regulation to Control Human Plasma Cell Differentiation
J. Immunol.,
April 1, 2008;
180(7):
4805 - 4815.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
